Tag: Nerve Disorders

Approval of Daybue applies to adults and children aged 2 years and older

Durable pain relief and neurological improvement observed, with most of benefit retained at 24 months

Increased odds of 30-day mortality ranges from 2.46 to 1.23 for nontraumatic coma and stroke

However, more frequent headache, dizziness, constipation, increased urine output seen for patients receiving difelikefalin versus placebo

Presence of RLS associated with significantly more severe psoriasis and more severe systemic inflammation

Rates of migraine higher in association with median nerve decompression, multiple nerve decompressions

Use of most new-to-market meds was <20 percent; costs for these medications were substantially larger

Overall improvement in quality-of-life measures sustained, without any progressive or delayed complications

Associations seen for temperature extremes and variability with stroke, migraines, hospitalization in dementia, MS exacerbations

Reporting rate of Guillain-Barré syndrome higher compared with other vaccinations, but rate within incidence range for general population